AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%
Last update at 2024-04-22T20:03:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -58.57300M | -17.30900M | -29.74400M | -66.89400M | -70.48000M |
| Minority interest | - | - | - | - | - |
| Net income | -61.59600M | -17.91400M | -30.39100M | -66.54600M | -70.48000M |
| Selling general administrative | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M |
| Reconciled depreciation | 1.00M | 1.16M | 0.71M | 0.68M | 0.59M |
| Ebit | -54.23000M | -8.97500M | -28.97300M | -69.09100M | -73.27700M |
| Ebitda | -53.54600M | -8.92800M | -28.39100M | -66.55900M | -72.68300M |
| Depreciation and amortization | 0.68M | 0.05M | 0.58M | 2.53M | 0.59M |
| Non operating income net other | 0.68M | 0.05M | 0.58M | 2.53M | 2.20M |
| Operating income | -54.23000M | -8.97500M | -28.97300M | -69.09100M | -72.68300M |
| Other operating expenses | 174.47M | 158.21M | 137.59M | 128.38M | 117.19M |
| Interest expense | 3.71M | 4.86M | 1.35M | 0.34M | 0.00000M |
| Tax provision | 0.00000M | 0.60M | - | - | - |
| Interest income | 0.68M | 0.05M | 0.58M | 2.53M | 2.20M |
| Net interest income | -3.02300M | -4.81300M | -0.77100M | 2.20M | 2.20M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 1.32M | 3.52M | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.02M | 0.60M | 0.65M | -0.34800M | 2.20M |
| Total revenue | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M |
| Total operating expenses | 172.72M | 157.13M | 136.70M | 127.47M | 116.91M |
| Cost of revenue | 1.75M | 1.08M | 0.90M | 0.91M | 0.29M |
| Total other income expense net | -4.34300M | -8.33400M | -0.77100M | 2.20M | 2.20M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -58.57300M | -17.91400M | -29.74400M | -66.89400M | -70.48000M |
| Net income applicable to common shares | -58.57300M | -17.91400M | -29.74400M | -66.89400M | -70.48000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 134.28M | 167.33M | 110.38M | 147.57M | 139.11M |
| Intangible assets | 14.95M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 8.26M | 7.41M | 14.04M | 9.46M | 3.48M |
| Total liab | 147.90M | 136.95M | 76.35M | 93.75M | 29.23M |
| Total stockholder equity | -13.61600M | 30.37M | 34.03M | 53.81M | 109.88M |
| Deferred long term liab | - | - | - | - | 0.09M |
| Other current liab | 28.06M | 47.27M | 25.50M | 21.50M | 20.31M |
| Common stock | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Capital stock | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Retained earnings | -1382.45900M | -1323.88600M | -1305.97200M | -1276.22800M | -1209.33400M |
| Other liab | - | 52.73M | 5.04M | 6.50M | 1.50M |
| Good will | - | - | - | - | - |
| Other assets | 0.64M | 0.97M | 0.82M | 0.70M | 0.73M |
| Cash | 24.46M | 18.89M | 30.37M | 22.52M | 76.32M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 65.21M | 63.55M | 40.84M | 58.21M | 27.73M |
| Current deferred revenue | 13.51M | 2.60M | 3.02M | 25.29M | 1.03M |
| Net debt | 17.09M | 11.68M | 8.71M | 13.79M | -76.32200M |
| Short term debt | 1.13M | 9.89M | 8.62M | 7.27M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 41.55M | 30.57M | 39.09M | 36.31M | - |
| Other stockholder equity | 1368.82M | 1354.19M | 1339.83M | 1329.85M | 1319.07M |
| Property plant equipment | 0.86M | 11.89M | 2.68M | 2.16M | 1.39M |
| Total current assets | 115.90M | 154.47M | 88.98M | 119.00M | 136.99M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -28.56500M | 30.37M | 44.68M | 74.45M | 111.28M |
| Short term investments | 33.75M | 106.08M | 26.95M | 75.56M | 52.22M |
| Net receivables | 40.32M | 15.47M | 15.97M | 10.11M | 4.08M |
| Long term debt | 39.45M | 19.91M | 19.82M | 9.81M | - |
| Inventory | 9.12M | 6.62M | 1.64M | 1.35M | 0.89M |
| Accounts payable | 22.51M | 3.79M | 3.71M | 4.15M | 6.39M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.15300M | -0.10200M | -0.00400M | 0.02M | -0.02400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -1382.45900M | -1323.88600M | -1305.97200M | -1276.22800M | -1209.33400M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.64M | 0.97M | 0.82M | 0.70M | 0.73M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 18.38M | 12.86M | 21.39M | 28.56M | 2.12M |
| Capital lease obligations | 2.10M | 10.65M | 19.27M | 26.50M | - |
| Long term debt total | 39.45M | 19.91M | 19.82M | 9.81M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 72.33M | -79.40900M | 48.73M | -22.20100M | 26.07M |
| Change to liabilities | -3.54100M | -0.38100M | 3.42M | -1.05300M | 11.09M |
| Total cashflows from investing activities | 72.78M | -80.03600M | 47.47M | -23.65600M | 24.96M |
| Net borrowings | 19.54M | 19.54M | 9.97M | 9.79M | 9.79M |
| Total cash from financing activities | 6.55M | 62.67M | 12.57M | 11.37M | 71.89M |
| Change to operating activities | -4.38500M | 14.47M | -0.37400M | 1.04M | 2.85M |
| Net income | -58.57300M | -17.91400M | -29.74400M | -66.89400M | -70.48000M |
| Change in cash | 5.57M | -11.48300M | 7.85M | -53.80100M | 38.03M |
| Begin period cash flow | 18.89M | 30.37M | 22.52M | 76.32M | 38.29M |
| End period cash flow | 24.46M | 18.89M | 30.37M | 22.52M | 76.32M |
| Total cash from operating activities | -73.75800M | 5.88M | -52.18500M | -41.51000M | -58.82600M |
| Issuance of capital stock | - | - | 0.00000M | 0.00000M | 67.16M |
| Depreciation | 1.00M | 1.16M | 0.71M | 0.68M | 0.59M |
| Other cashflows from investing activities | 0.89M | - | - | -22.20100M | 26.07M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -2.37700M | -4.87500M | -0.12600M | -0.36600M | -0.83900M |
| Change to account receivables | -24.84800M | 0.50M | -5.86200M | -6.03400M | -4.07700M |
| Sale purchase of stock | 2.12M | 4.78M | 2.60M | 1.58M | 71.89M |
| Other cashflows from financing activities | 4.43M | 62.67M | 12.57M | 11.37M | 4.73M |
| Change to netincome | 13.07M | 12.91M | 7.30M | 9.12M | 7.70M |
| Capital expenditures | 0.45M | 0.63M | 1.26M | 1.46M | 1.11M |
| Change receivables | -24.84800M | 0.50M | -5.86200M | -6.03400M | -4.07700M |
| Cash flows other operating | 1.58M | 5.63M | -27.75600M | 24.11M | -2.05100M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 5.57M | -11.48300M | 7.85M | -53.80100M | 38.03M |
| Change in working capital | -29.04900M | 9.72M | -30.32200M | 16.66M | 4.12M |
| Stock based compensation | 12.38M | 9.49M | 7.30M | 9.12M | 7.70M |
| Other non cash items | 0.48M | 3.14M | -0.12200M | -1.07300M | -0.76600M |
| Free cash flow | -74.20800M | 5.25M | -53.44700M | -42.96500M | -59.93200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals Inc |
0.05 4.63% | 1.13 | - | - | 1.66 | 31.64 | 1.61 | -12.4326 |
| NVO Novo Nordisk A/S |
2.55 2.08% | 125.26 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.76 3.07% | 126.26 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.64 1.43% | 399.92 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
2.35 2.71% | 89.17 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
1180 Veterans Boulevard, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Mr. Raul R. Rodriguez | Pres, CEO & Director | 1961 |
| Mr. Dean L. Schorno CPA | Exec. VP & CFO | 1963 |
| Dr. Wolfgang Dummer M.D., Ph.D. | Exec. VP & Chief Medical Officer | 1966 |
| Mr. David A. Santos | Exec. VP & Chief Commercial Officer | 1963 |
| Mr. Joseph Lasaga | Exec. VP of Corp. Devel. | 1975 |
| Ms. Julie Patel | Sr. VP of HR | NA |
| Dr. Esteban S. Masuda | Exec. VP of Research | 1962 |
| Mr. Tarek Sallam | VP of Marketing | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...